

Remarks

Currently Claims 1-11, 15 and 17-24 are pending. Applicants respectfully submit that claim 17 was erroneously mis-numbered as claim 15. Applicants have correctly referred to this claim as claim 17 in the instant amendment. Applicants request that the Examiner acknowledge the correction of claim numbering.

Claims 12-14 are canceled. Claim 16 is canceled and re-written as new claims 19-21.

Claims 1-11, 15 and 17 are amended herein. Claim 1 is amended to correct the subscripts in the various chemical formulas, to change "represents" to "is" or "are" as appropriate, to correct an obvious clerical error and to change plural to singular. Claim 2 is amended to delete the alternative embodiment, which is recited in new claim 18. Claims 3 and 7 are amended to remove the parenthetical subspecies embodiment. Claims 3-11, 15 and 17 are amended to remove multiple dependencies to reduce claim fees. Claim 8 is further amended to correct an obvious clerical error. Claim 17 is amended to correct the subscripts in the chemical formula and to recite the steps of the process in active tense. The foregoing amendments do not narrow the scope of the claims and are not made for reasons of patentability. No new matter is added.


New claims 18-26 are added. Support for new claim 18 can be found in Applicants' specification, including at original claim 2. Support for new claims 19-21 can be found in Applicants' specification, including at original claim 16. Support for new claims 22-23 can be found in Applicants' specification, including at page 12, lines 9-13. Support for new claim 24 can be found in Applicants' specification, including at page 13, line 38. No new matter is added.

Applicants have also amended the specification to correct a typographical error in the title, to recite priority application information and to provide an abstract on a separate page.

Entry of the foregoing amendments is respectfully requested.

Applicants respectfully submit that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at (919) 483-8222, to discuss this case, if desired.

Respectfully submitted,



Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

LL
Date: 20 July, 2004
GlaxoSmithKline Inc.
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222
fax: (919) 483-7988
email: Lorie.A.Morgan@gsk.com